Global Drug Repurposing Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Drug Repurposing market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Drug Repurposing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Drug Repurposing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Drug Repurposing market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Drug Repurposing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Drug Repurposing market include Novartis, Pfizer, AbbVie, NuMedii, Biovista, Astellas Pharma and Allergan, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Drug Repurposing, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Drug Repurposing, also provides the value of main regions and countries. Of the upcoming market potential for Drug Repurposing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drug Repurposing revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Drug Repurposing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Drug Repurposing company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Drug Repurposing Segment by Company
Novartis
Pfizer
AbbVie
NuMedii
Biovista
Astellas Pharma
Allergan
Drug Repurposing Segment by Type
Neurodegenerative Diseases
CNS Diseases
Oncology
Others
Drug Repurposing Segment by Application
Hospitals
Ambulatory Surgical Centers
Others
Drug Repurposing Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Drug Repurposing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Drug Repurposing key companies, revenue, market share, and recent developments.
3. To split the Drug Repurposing breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Drug Repurposing market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Drug Repurposing significant trends, drivers, influence factors in global and regions.
6. To analyze Drug Repurposing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Repurposing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drug Repurposing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Repurposing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Repurposing industry.
Chapter 3: Detailed analysis of Drug Repurposing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Drug Repurposing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Drug Repurposing in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Drug Repurposing market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Drug Repurposing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Drug Repurposing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Drug Repurposing market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Drug Repurposing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Drug Repurposing market include Novartis, Pfizer, AbbVie, NuMedii, Biovista, Astellas Pharma and Allergan, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Drug Repurposing, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Drug Repurposing, also provides the value of main regions and countries. Of the upcoming market potential for Drug Repurposing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drug Repurposing revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Drug Repurposing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Drug Repurposing company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Drug Repurposing Segment by Company
Novartis
Pfizer
AbbVie
NuMedii
Biovista
Astellas Pharma
Allergan
Drug Repurposing Segment by Type
Neurodegenerative Diseases
CNS Diseases
Oncology
Others
Drug Repurposing Segment by Application
Hospitals
Ambulatory Surgical Centers
Others
Drug Repurposing Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Drug Repurposing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Drug Repurposing key companies, revenue, market share, and recent developments.
3. To split the Drug Repurposing breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Drug Repurposing market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Drug Repurposing significant trends, drivers, influence factors in global and regions.
6. To analyze Drug Repurposing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Repurposing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drug Repurposing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Repurposing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Repurposing industry.
Chapter 3: Detailed analysis of Drug Repurposing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Drug Repurposing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Drug Repurposing in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
192 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Drug Repurposing Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Drug Repurposing Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Drug Repurposing Market Dynamics
- 2.1 Drug Repurposing Industry Trends
- 2.2 Drug Repurposing Industry Drivers
- 2.3 Drug Repurposing Industry Opportunities and Challenges
- 2.4 Drug Repurposing Industry Restraints
- 3 Drug Repurposing Market by Company
- 3.1 Global Drug Repurposing Company Revenue Ranking in 2024
- 3.2 Global Drug Repurposing Revenue by Company (2020-2025)
- 3.3 Global Drug Repurposing Company Ranking (2023-2025)
- 3.4 Global Drug Repurposing Company Manufacturing Base and Headquarters
- 3.5 Global Drug Repurposing Company Product Type and Application
- 3.6 Global Drug Repurposing Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Drug Repurposing Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Drug Repurposing Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Drug Repurposing Market by Type
- 4.1 Drug Repurposing Type Introduction
- 4.1.1 Neurodegenerative Diseases
- 4.1.2 CNS Diseases
- 4.1.3 Oncology
- 4.1.4 Others
- 4.2 Global Drug Repurposing Sales Value by Type
- 4.2.1 Global Drug Repurposing Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Drug Repurposing Sales Value by Type (2020-2031)
- 4.2.3 Global Drug Repurposing Sales Value Share by Type (2020-2031)
- 5 Drug Repurposing Market by Application
- 5.1 Drug Repurposing Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Ambulatory Surgical Centers
- 5.1.3 Others
- 5.2 Global Drug Repurposing Sales Value by Application
- 5.2.1 Global Drug Repurposing Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Drug Repurposing Sales Value by Application (2020-2031)
- 5.2.3 Global Drug Repurposing Sales Value Share by Application (2020-2031)
- 6 Drug Repurposing Regional Value Analysis
- 6.1 Global Drug Repurposing Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Drug Repurposing Sales Value by Region (2020-2031)
- 6.2.1 Global Drug Repurposing Sales Value by Region: 2020-2025
- 6.2.2 Global Drug Repurposing Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Drug Repurposing Sales Value (2020-2031)
- 6.3.2 North America Drug Repurposing Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Drug Repurposing Sales Value (2020-2031)
- 6.4.2 Europe Drug Repurposing Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Drug Repurposing Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Drug Repurposing Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Drug Repurposing Sales Value (2020-2031)
- 6.6.2 South America Drug Repurposing Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Drug Repurposing Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Drug Repurposing Sales Value Share by Country, 2024 VS 2031
- 7 Drug Repurposing Country-level Value Analysis
- 7.1 Global Drug Repurposing Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Drug Repurposing Sales Value by Country (2020-2031)
- 7.2.1 Global Drug Repurposing Sales Value by Country (2020-2025)
- 7.2.2 Global Drug Repurposing Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.7.2 France Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.14.2 China Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.17.2 India Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Drug Repurposing Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Drug Repurposing Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Drug Repurposing Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Novartis
- 8.1.1 Novartis Comapny Information
- 8.1.2 Novartis Business Overview
- 8.1.3 Novartis Drug Repurposing Revenue and Gross Margin (2020-2025)
- 8.1.4 Novartis Drug Repurposing Product Portfolio
- 8.1.5 Novartis Recent Developments
- 8.2 Pfizer
- 8.2.1 Pfizer Comapny Information
- 8.2.2 Pfizer Business Overview
- 8.2.3 Pfizer Drug Repurposing Revenue and Gross Margin (2020-2025)
- 8.2.4 Pfizer Drug Repurposing Product Portfolio
- 8.2.5 Pfizer Recent Developments
- 8.3 AbbVie
- 8.3.1 AbbVie Comapny Information
- 8.3.2 AbbVie Business Overview
- 8.3.3 AbbVie Drug Repurposing Revenue and Gross Margin (2020-2025)
- 8.3.4 AbbVie Drug Repurposing Product Portfolio
- 8.3.5 AbbVie Recent Developments
- 8.4 NuMedii
- 8.4.1 NuMedii Comapny Information
- 8.4.2 NuMedii Business Overview
- 8.4.3 NuMedii Drug Repurposing Revenue and Gross Margin (2020-2025)
- 8.4.4 NuMedii Drug Repurposing Product Portfolio
- 8.4.5 NuMedii Recent Developments
- 8.5 Biovista
- 8.5.1 Biovista Comapny Information
- 8.5.2 Biovista Business Overview
- 8.5.3 Biovista Drug Repurposing Revenue and Gross Margin (2020-2025)
- 8.5.4 Biovista Drug Repurposing Product Portfolio
- 8.5.5 Biovista Recent Developments
- 8.6 Astellas Pharma
- 8.6.1 Astellas Pharma Comapny Information
- 8.6.2 Astellas Pharma Business Overview
- 8.6.3 Astellas Pharma Drug Repurposing Revenue and Gross Margin (2020-2025)
- 8.6.4 Astellas Pharma Drug Repurposing Product Portfolio
- 8.6.5 Astellas Pharma Recent Developments
- 8.7 Allergan
- 8.7.1 Allergan Comapny Information
- 8.7.2 Allergan Business Overview
- 8.7.3 Allergan Drug Repurposing Revenue and Gross Margin (2020-2025)
- 8.7.4 Allergan Drug Repurposing Product Portfolio
- 8.7.5 Allergan Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


